Table 1.
Baseline characteristics of propensity score matched patients who received 10-day decitabine with venetoclax, and intensive chemotherapy
| Patient characteristics | 10-day decitabine and venetoclax (N=85) |
Intensive chemotherapy (N=85) |
p |
|---|---|---|---|
| Age, years | 72 [69–78] | 73 [67–76] | .24 |
| Age ≥ 70 years | 63 (74) | 55 (65) | .18 |
| Age ≥ 80 years | 15 (18) | 10 (12) | .28 |
| Male sex | 45 (53) | 48 (56) | .64 |
| ECOG Performance Status | |||
| 0–1 | 55 (65) | 58 (68) | .63 |
| ≥2 | 30 (35) | 27 (32) | |
| Bone marrow blasts, % | 45 [22–62] | 65 [38–84] | <.01 |
| Diagnosis | |||
| De novo AML | 55 (65) | 59 (69) | |
| Secondary AML with AHD | 15 (18) | 9 (11) | .38 |
| Therapy-related AML | 16 (19) | 19 (22) | |
| Prior therapies | 0 (0) | 0 (0) | NA |
| ELN 2017 cytogenetic risk group | |||
| Favorable | 0 (0) | 0 (0) | |
| Intermediate | 44 (52) | 33 (39) | .08 |
| Adverse | 40 (47) | 52 (61) | |
| FLT3-ITD/TKD | 14 (16) | 22 (24) | .09 |
| ELN 2017 risk group | |||
| Favorable | 19 (22) | 14 (16) | |
| Intermediate | 11 (13) | 17 (20) | .36 |
| Adverse | 55 (65) | 54 (64) | |
| Stem-cell transplantation after response | 12 (14) | 7 (8) | .23 |
| Treatment-related mortality (TRM) risk | |||
| High (TRM score >13.1) | 24 (28) | 24 (28) | 1.00 |
| Low (TRM score ≤13.1) | 61 (72) | 61 (72) | |
| Expected TRM rate, %, mean ± SD1 | 12 ± 12 | 14 ± 14 | .27 |
Results reported as n (%), or median [interquartile range]. ECOG = Eastern Co-operative Oncology Group, AHD = antecedent hematological disorder, ELN = European LeukemiaNet.
1.
Expected mortality with intensive chemotherapy using the TRM model.